TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
Recruiting · NCT06310330 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Comprehensive echocardiographic follow-upSimplified echocardiographic follow-up
What this trial is about
TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD). Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Breast cancer and referral for follow-up to identify potential CTRCD
Exclusion criteria
- Not willing or able to consent
Where it is running
1 location listed.
- St. Olavs hospital - Trondheim, Norway